Navigation Links
OncoGenex Pharmaceuticals, Inc. Provides Update on Clinical Development Program and Reports Financial Results for Fourth Quarter and Year End 2012
Date:3/7/2013

98 per diluted common share, and $14.7 million, or $1.51 per diluted common share, respectively. The net loss in the years ended December 31, 2012 and 2011 included a non-cash gain on revaluation of our warrant liability of $4.5 million and $7.4 million, respectively. 
  • We had $75.4 million in cash, cash equivalents and short-term investments as of December 31, 2012, compared to $64.9 million as of December 31, 2011.
  • 2013 cash guidance:
  • Net cash requirements are expected to be in the range of $40 million to $50 million.
  • Year-end cash, cash equivalents and investments are expected to be in the range of $25 million to $35 million.
  • Based on our current expectations, we believe our capital resources as of December 31, 2012 will be sufficient to fund our currently planned operations into 2015.
  • At March 7, 2013, we had 14,658,766 shares outstanding.
  •  Consolidated Statements of Loss(In thousands, except per share and share data)(unaudited)Three months ended December 31,Year ended December 31,2012201120122011Collaboration revenue$
    9,780$
    ,236$
    20,095$
    5,496Operating expenses:  Research and development15,6457,47739,94821,553  General and administrative2,0421,7317,7916,230  Restructuring gain(1,657)-(1,657)-Total operating expenses16,0309,20846,08227,783Loss from operations6,2507,97225,98722,287  Other income (expense)2,147(1,596)4,8897,614Loss for the period before income taxes(4,103)(9,568)(21,098)(14,673)  Income taxes----Net loss$
    (4,103)$
    (9,568)$   (21,098)$ (14,673)Basic and diluted net loss per share$
    (0.28)$
    (0.98)$
    (1.56)$
    (1.51)Weighted average number of basic and diluted common shares14,656,7939,748,63913,522,7239,729,340Consolidated Balance Sheets(In thousands) December 31,  December 31, 20122011 (unaudited) Assets:  Cash, cash equivalents, short term investments and restricted cash$
    75,697$
    '/>"/>

    SOURCE OncoGenex Pharmaceuticals, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related medicine technology :

    1. OncoGenex Pharmaceuticals, Inc. Reports Second Quarter and First-Half 2012 Financial Results and Reviews Clinical Development Highlights for Custirsen and OGX-427
    2. OncoGenex Announces Initiation of the Phase 3 "AFFINITY" Trial for Patients with Advanced Prostate Cancer
    3. OncoGenex Announces Plans for the Initiation of the Borealis-2 Clinical Trial Evaluating OGX-427 in Combination with Second-Line Therapy for Bladder Cancer
    4. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
    5. Provectus Pharmaceuticals, Inc.s Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
    6. Keryx Biopharmaceuticals, Inc. To Host Conference Call on First Quarter 2012 Financial Results
    7. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2012 Financial Results
    8. Auxilium Pharmaceuticals, Inc. to Present At The BofAML 2012 Health Care Conference
    9. Depomed Announces Receipt of $1 million Milestone Payment From Ironwood Pharmaceuticals, Inc.
    10. Auxilium Pharmaceuticals, Inc. and FCB I LLC Announce the Issuance of Composition of Matter Patent Covering Testim
    11. Auxilium Pharmaceuticals, Inc. Raises Revenue Guidance And Reduces Net Loss Guidance For 2012
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:10/22/2014)... N.J. , Oct. 22, 2014  Rescheduling ... major transformation in the pain market, according to ... Insights, Inc., a firm providing market research and ... Photo - http://photos.prnewswire.com/prnh/20141021/153440 ... scheduling change for hydrocodone combination products from Schedule ...
    (Date:10/22/2014)... 2014   Reproductive Medicine Associates of New ... field of infertility, presents new clinical research examining ... research abstract, released during the 70 th ... in Honolulu, Hawaii , combines ... (SGD) pre-implantation genetic diagnosis (PGD). Results ...
    (Date:10/22/2014)... Inc. (NYSE: CRY ), a leading medical ... vascular surgery, announced today that James Patrick (Pat) ... elected to the Company,s Board of Directors, effective October ... Executive Chairman of CryoLife, stated, "Since joining the Company in ... who is well positioned to maximize CryoLife,s potential.  His ...
    Breaking Medicine Technology:Hydrocodone: Rescheduled, Repositioned & Reinvented 2Hydrocodone: Rescheduled, Repositioned & Reinvented 3New IVF Research Highlights Improved Genetic Screening Approach To Help Parents Have Healthier Babies 2New IVF Research Highlights Improved Genetic Screening Approach To Help Parents Have Healthier Babies 3Pat Mackin Joins CryoLife Board of Directors 2Pat Mackin Joins CryoLife Board of Directors 3
    (Date:10/22/2014)... Best Cheap Hosting USA is among the most ... recently announced that iPower ( http://www.best-cheap-hosting-usa.com/go/iPower/ ) is the ... the world. , “iPower is one of the most ... various kinds of useful products for new and old ... customer service and a number of features which will ...
    (Date:10/22/2014)... of Prussia, PA (PRWEB) October 22, 2014 ... is recognized as an industry leader with over 25 ... award winning team leader in the areas related to ... addition, Mr. Carlson is an Editorial Advisory Board member ... Healthcare Council Educator. Blue Fin Group is a ...
    (Date:10/22/2014)... HealthDay Reporter , TUESDAY, Oct. ... men may lead to increased blood pressure, according to a ... rise in blood pressure for young adult women or for ... women drank lightly or moderately, their risk of high blood ... finding parallels studies in older adult men and women," said ...
    (Date:10/20/2014)... The newly updated Worldwide Medical Market Forecasts to ... figures and forecasts on the global medical markets. , ... the Worldwide Medical Market Forecasts to 2019 ... the worldwide medical market to reveal key insights into ... for 2010-2019, covering each country market individually, allowing you ...
    (Date:10/20/2014)... (PRWEB) October 20, 2014 Women’s health ... in Obstetrics & Gynecology of Columbus, Inc., A Division ... healthcare services to more than 100,000 patients annually. Dr. ... all ages and stages of a women’s life. She ... locations in Westerville and Dublin. , Dr. Murphy ...
    Breaking Medicine News(10 mins):Health News:Best Cheap Hosting USA Has Recently Announced The Best Cheap Web Hosting Companies In 2014 2Health News:Rich Carlson and Marc Duey to Hold Workshop at CBI’s Specialty Pharmacy and Distribution Networks Conference 2Health News:Binge Drinking May Boost Blood Pressure in Young Men 2Health News:Binge Drinking May Boost Blood Pressure in Young Men 3Health News:Binge Drinking May Boost Blood Pressure in Young Men 4Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 2Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 3Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 4Health News:OhioHealth Welcomes New Women’s Health Specialist to MaternOhio Specialists in Obstetrics & Gynecology of Columbus, Inc. 2Health News:OhioHealth Welcomes New Women’s Health Specialist to MaternOhio Specialists in Obstetrics & Gynecology of Columbus, Inc. 3
    ... research suggests that testosterone replacement therapy for men with ... the prostate gland, contrary to some reports that this ... the November 15 issue of JAMA, a theme issue ... of the Urological Sciences Research Foundation and University of ...
    ... completely prevented the development of bone tumors in 50 ... providing early evidence that it could treat, or thwart, ... a number of cancers when they start to spread. ... D. Anderson Cancer Center reported in the journal Cancer ...
    ... symptoms who received a combination therapy were more likely to ... medication, according to a study in the November 15 issue ... ,Steven A. Kaplan, M.D., of Weill Cornell Medical College, ... a JAMA media briefing on men's health in New York. ...
    ... Family Welfare Minister has said that to shut out ... name of safety would be// against the interest of ... two day International Conclave on Traditional Medicine, which he ... society we live in today, a significant segment of ...
    ... been sequencing the genome of an organism called Mycobacterium-w ... complete// genome that holds promise in the treatment of ... evidence that a vaccine made from killed Mw drastically ... resistant (MDR) variety is driving this project more than ...
    ... medical research team looking for a cure for Duchenne Muscular ... submitted their findings// recently. ,The Stem cell Studies ... hope for those who suffer from the disease. ... genetic origin that results in muscle wasting which usually ...
    Cached Medicine News:Health News:Testosterone Replacement Therapy Appears Safe for Prostate 2Health News:"Trojan Horse" Agent Halts Bone Metastasis in Mice 2Health News:"Trojan Horse" Agent Halts Bone Metastasis in Mice 3Health News:Combination Therapy More Effective for Treating Lower Urinary Tract Symptoms 2Health News:Two Day International Conclave on Traditional Medicine Inaugurated 2Health News:Two Day International Conclave on Traditional Medicine Inaugurated 3Health News:India Finds New Use for an Old Bug 2Health News:India Finds New Use for an Old Bug 3
    ... drainage from the ureteropelvic junction to the ... ease of placement and patient compliance. The ... repositioning and ease of removal. AQ® is ... when activated, attracts and holds water and ...
    The ARC Laser MISC combines a pharo unit + Lyla laser module = Photolysis....
    ... IgM Capture ELISA is for the qualitative ... recombinant antigens (WNRA) in serum as an ... West Nile virus infection in patients with ... must be confirmed by Plaque Reduction Neutralization ...
    Adult; dilates 6.0 to 34.0 French; individually packaged, sterile....
    Medicine Products: